Young J A, Dillman R O, Seagren S L, Taetle R, Rentschler R E, Lea J W, Lehar T J, Green M R, Stanton W, Mendelsohn J, Royston I
Cancer Treat Rep. 1982 Jun;66(6):1399-401.
Fifty-six patients with small cell carcinoma of the lung were treated with a two-cyclic induction course of hexamethylmelamine, vincristine, doxorubicin, and cyclophosphamide. Patients with limited disease (LD) who responded and patients with extensive disease (ED) who had a complete response received prophylactic whole-brain radiotherapy, as well as radiotherapy to thoracic and abdominal sites of disease. Concurrently with radiotherapy, consolidation chemotherapy was given with doxorubicin, cyclophosphamide, methotrexate, and etoposide. The complete response rate was 35% for ED patients and 68% for LD patients. The median survival time for complete responders was 54 weeks for ED patients and 65 weeks for LD patients. The toxicity of the program was moderate, and the effectiveness was comparable to that of other reported combined-modality treatment programs.
56例小细胞肺癌患者接受了六甲蜜胺、长春新碱、阿霉素和环磷酰胺的两周期诱导治疗。有反应的局限性疾病（LD）患者和完全缓解的广泛期疾病（ED）患者接受了预防性全脑放疗以及对胸部和腹部疾病部位的放疗。在放疗的同时，给予阿霉素、环磷酰胺、甲氨蝶呤和依托泊苷进行巩固化疗。ED患者的完全缓解率为35%，LD患者为68%。完全缓解者的中位生存时间，ED患者为54周，LD患者为65周。该方案的毒性为中度，疗效与其他报道的综合治疗方案相当。
